Effectiveness and Safety Evaluation of Qixiong Zhongzi Decoction () in Idiopathic Asthenozoospermia Treatment: A Randomized Controlled Trial / 中国结合医学杂志

OBJECTIVE@#To evaluate the clinical effectiveness and safety of the Chinese medicine (CM) Qixiong Zhongzi Decoction (, QZD) in the treatment of patients with idiopathic asthenozoospermia.@*METHODS@#A total number of 66 patients with idiopathic asthenozoospermia were included and randomly divided into treatment and control groups by SAS-generated code from January 2015 to August 2016, 33 patients in each group. Patients in the treatment group were administered with 150 mL of QZD twice a day, whereas those in the control group were given 1 g of levocarnitine oral liquid twice a day. The two groups received the indicated medication for 12 weeks and were then followed up for 4 weeks. The primary outcome was sperm motility, and the secondary therapeutic indices were sperm volume, density, pregnancy probability, and CM syndrome score. The comparison between groups was carried out at 4, 8 and 12 weeks, respectively. The safety was determined before and after treatment.@*RESULTS@#(1) Drop-off: 5 cases (7.58%) were lost after treatment (2 from the treatment group and 3 from the control group). (2) Primary outcomes: after 8- and 12-week treatment, the progressive sperms in the two groups were significantly higher than the baseline (all P0.05), however, the CM syndrome score of the treatment group significantly declined compared with baseline level at each time points (all P<0.05). (4) Safety: no obvious side reactions were found during the treatment in both groups.@*CONCLUSION@#QZD could improve the progressive and non-progressive grade sperm in the treatment of idiopathic asthenozoospermia. It is safe with no obvious side effects.

Effect of Longbishu capsule () plus doxazosin on benign prostatic hyperplasia: a randomized controlled trial / 中国结合医学杂志

<p><b>OBJECTIVE</b>To investigate the effect of Longbishu Capsule (, LBS), doxazosin, and combination therapy on benign prostatic hyperplasia (BPH).</p><p><b>METHODS</b>A randomized, double-blind, multi-center parallel trial was conducted involving 360 patients in hospitals in Beijing (108 cases), Heilongjiang (90 cases), Sichuan (90 cases), Shanghai (72 cases), China. They were randomly assigned with central randomization method to group A (LBS placebo plus doxazosin), group B (LBS plus doxazosin) or group C (LBS plus doxazosin placebo), 120 cases for each group. The international prostate symptom score, maximum urinary flow rate, postvoid residual urine volume and prostate volume were measured for evaluating the efficacy of the three treatments.</p><p><b>RESULTS</b>At baseline, there was no significant difference in the measured variables among the three groups. After 12-month treatment, the three groups showed significant improvements in IPSS and maximum urinary flow rate from baseline (P<0.01). Although postvoid residual urine volume was not significantly different from the baseline in group A (P>0.05), it significantly decreased in group B and C (P<0.05). The incidence of adverse events were similar among the three groups.</p><p><b>CONCLUSIONS</b>The treatment of LBS alone or LBS plus doxazosin was able to significantly improve IPSS in patients with BPH. The treatments may reduce the increase in prostate volume and postvoid residual urine volume as well.</p>

Treatment of oligospermia/asthenozoospermia patients by three different Chinese medical principles: a randomized control clinical study / 中国中西医结合杂志

<p><b>OBJECTIVE</b>To assess the efficacy and safety of three different Chinese medical principles in treating patients with male infertility (oligospermia/asthenozoospermia).</p><p><b>METHODS</b>Totally 128 patients with male infertility were classified into 3 groups, i.e., Shen-essence deficiency syndrome, Pi-Shen deficiency syndrome, Shen-deficiency blood-stasis syndrome. They were assigned to the Chinese medical treatment group (96 cases) and the Western medical treatment group (32 cases) by stratified randomization in the ratio of 3: 1. Those in the Chinese medical treatment group were treated with Chinese drugs for Shen invigorating and blood activating, Shen invigorating and Pi supplementing, Shen-qi benefiting. Those in the Western medical treatment group were treated with Clomifene (at the daily dose of 25 mg per day, once daily). Three months consisted of one therapeutic course. The parameters of semen, the pregnancy rate, and adverse reactions were observed.</p><p><b>RESULTS</b>Totally 24 patients dropped out in the two group, 17 in the Chinese medical treatment group (9 patients of Shen deficiency blood stasis syndrome, 5 of Shen-Pi deficiency syndrome, and 3 of Shen-essence deficiency syndrome) and 7 in the Western medical treatment group. Compared with before treatment, there was no statistical difference in the improvement of semen amount at 3 months after treatment between the two groups (P > 0.05). There was statistical difference in the improvement of semen density, class A semen, class A +B semen, and 1-h activity ratio (P < 0.05). The improvement was most obvious in Shen deficiency blood stasis syndrome, followed by Shen-Pi deficiency syndrome and Shen-essence deficiency syndrome. The improvement was the weakest in the Western medical treatment group. There was no statistical difference in the improvement of semen amount, semen density, class A semen, or 1-h activity ratio at 3 months after treatment between the two groups (P > 0.05). Best effect was obtained in improving class A + B semen quality in patients of Shen deficiency blood stasis syndrome, showing statistical difference when compared with the other two syndrome types and the Western medical treatment group (P < 0.05, P < 0.01). No obvious adverse reaction occurred in the two groups during the treatment course.</p><p><b>CONCLUSION</b>Shen invigorating and blood activating method could improve the semen density and semen activities, and it was superior to other therapeutic methods.</p>

Thought of treating erectile dysfunction by integrative medicine / 中国中西医结合杂志

Erectile dysfunction (ED) was explored to improve the clinical efficacy in terms of disease identification and syndrome typing, macroscopic and microscopic combination, complementary therapy of Chinese medicine (CM) and Western medicine (WM), and evidence-based medicine (EBM) research methods. And the advantages and disadvantages of CM and WM in treatment of ED were briefly analyzed. How to treat ED by integrative medicine was also addressed

Thinking and methods for treatment of benign prostatic hyperplasia with integrative medicine / 中国中西医结合杂志

Benign prostate hyperplasia (BPH) is commonly encountered in males more than 50-years-old, its clinical symptom is mainly manifestated as the dysuresia, which could seriously affect the health and quality of life of aged persons. It was suggested in this paper that the integrated medical treatment for BPH should put prominence to the characteristics of traditional Chinese medicine (TCM), go on the way of combining disease with syndrome and integrating macroscopic with microscopic treatment. Moreover, some methods are proposed, such as to establish practical animal model, unfold experimental research, create TCM efficacy evaluating system, improve dosage form of Chinese drugs, so as to explore the thinking ways for treatment of BPH with integrated medicine.

Clinical observation on ziyin tongbi decoction in treating benign prostatic hyperplasia / 中国中西医结合杂志

<p><b>OBJECTIVE</b>To evaluate the efficacy and safety of Ziyin Tongbi Decoction (ZTD) in treating benign prostatic hyperplasia (BPH).</p><p><b>METHODS</b>Adopting randomized positive controlled clinical trial method, the 100 BPH patients were assigned to two groups equally. The treatment group was medicated with ZTD, one dose per day, consisting of wild weed 12 g, yellow cocktree bark 12 g, rehmannia root 10 g, Chinese yam 15 g, bitter cardamon 10 g, red sage root 10 g, burreed tuber 8 g, tumeric rhizome 8 g, mantis egg-case 8 g, ground beetle 8 g, Zhejiang fritillary bulb 10 g, and prunella spike 15 g, etc., by decocting with water, taking twice daily and 150 mL each time. The control group was treated by Longbishu Capsule, a product of Kedi Pharmaceutical Co., Ltd., consisting of psoralea fruit, motherwort, and lysimachia, etc., twice a day, 0.9 g each time. A course of 4 weeks was given to both groups. The therapeutic efficacy was evaluated by changes in TCM symptoms after treatment (including frequency of night urination, degree of dysuria, condition of urinary thread, soreness and weakness in loin and knees, lower abdominal distention, spiritless and general weakness), the International Prostate Syndrome Score (I-PSS), maximum flow rate (Qmax), residual urine volume and prostate volume.</p><p><b>RESULTS</b>The TCM symptoms were improved in the treatment group after treatment, showing significant as compared with those before treatment (P < 0.05); as compared with the control group, the difference in urinary thread and lower abdominal distention in treatment group was significant improved (P < 0.05). The total effective rate in the treatment group was 89.00% (43/48), while that in the control group was 73.46% (36/49), showing statistically significant difference between them (P < 0.01). The efficacy in the treatment group in aspect of improving I-PSS and Qmax was better than that in the control group (P < 0.05, P < 0.01). The residual urine volume was reduced in both group, as compared with that before treatment (P < 0.05), but showed no significant difference between the two groups (P > 0.05). No obvious change of the prostate volume was found in both two groups after treatment (P > 0.05). There are 4 patients in the treatment group and 5 in the control group complained of slight adverse reactions as gastric discomfort and dry mouth, but these were not attended and showed no affection on the treatment.</p><p><b>CONCLUSION</b>ZTD is effective and safe for the treatment of benign prostatic hyperplasia.</p>

Effect of Qianlie Huazhuo Capsule for treatment of chronic prostatitis of dampness-heat stagnancy type / 中国中西医结合杂志

<p><b>OBJECTIVE</b>To evaluate the therapeutic effects of Qianlie Huazhuo Capsule (QHC) on patients with chronic prostatitis of dampness-heat stagnancy type (CP-DHS).</p><p><b>METHODS</b>Sixty-five patients were randomly assigned to the treatment group (32 cases) treated with QHC and the control group (33 cases) treated with Qianlie Jiedu Capsule, for 1 month respectively. The clinical efficacy was evaluated at the end of the 2nd and 4th month, their quality of life (QOL) was estimated by NIH Chronic Prostatitis Syndrome Index (NIH-CPSI) and patients' capacity was estimated by SF-12 scale as well.</p><p><b>RESULTS</b>Out of patients in the treatment group, 2 got cured, notable effect showed in 15, effective in 9, and ineffective in 6, the total effective rate being 81.2%, while in the 33 patients of the control group, 2 got cured, notable effect in 5, effective in 13 and ineffective in 13, the total effective rate 60.6%, the difference between the two groups was statistically significant in the total efficacy (P < 0.05). As compared with the control group, the NIH-CPSI score for QOL was significantly lower, SF-12 physical capacity score was better in the treatment group (both P < 0.05), and SF-12 mental capacity score in the two groups showed insignificant difference.</p><p><b>CONCLUSION</b>QHC could obtain good effect for the treatment of CP-DHS.</p>

Clinical observation on treatment of oligospermia and asthenospermia with Liuwu Shengjing Decoction / 中国中西医结合杂志

<p><b>OBJECTIVE</b>To investigate the clinical efficacy and safety of Liuwu Shengjing Decoction (LWD) in treating oligospermia and asthenospermia.</p><p><b>METHODS</b>One hundred and fourteen patients were randomized into two groups, the treated group administrated with self-formulated LWD, and the control group administrated with Wuzi Yanzong Pill (WYP). All were treated for 3 months. Patients' semen was analyzed before and after treatment, and the therapeutic efficacy was evaluated.</p><p><b>RESULTS</b>The total effective rate was 94.8% in the treated group, with a partner pregnant rate of 8.6% (5/58), while in the control group, they were 85.7% and 5.4% (3/56) respectively. The efficacy in the treated group was better (P = 0.03). Patients' sperm count and viability of sperm were improved in both groups (P < 0.05 or P < 0.01), but the improvement in the treated group was superior (P < 0.05).</p><p><b>CONCLUSION</b>LWD could effectively improve the condition of male infertility with oligospermia and asthenospermia.</p>